<DOC>
	<DOCNO>NCT00483041</DOCNO>
	<brief_summary>To evaluate effect MEDI-528 adult atopic asthma .</brief_summary>
	<brief_title>A Study Evaluate Effect Single-Dose Intravenous Administration MEDI-528</brief_title>
	<detailed_description>To evaluate effect MEDI-528 change biologically active IL-9 level BAL fluid follow segmental allergen challenge adult atopic asthma .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<criteria>Male female adult , age 18 50 year age time screen ; Written inform consent obtain patient prior receipt study medication begin study procedure ; Previously document diagnosis asthma base episodic symptom airflow obstruction wheeze chest tightness , alternative diagnosis ( eg , chronic obstructive pulmonary disease ) rule ; Forced expiratory volume one second ( FEV1 ) ≥ 70 % predict value ; A positive skin prick intradermal test cat allergen extract , short ragweed allergen extract , dust mite allergen extract . A positive skin test define induration skin test wheal least 2 mm great diameter induration control skin wheal ; History asthmatic symptom upon exposure least one allergen ( cat allergen extract , short ragweed allergen extract , dust mite allergen extract ) induces positive skin prick test ; AHR methacholine inhalation challenge test , PC20 ≤ 8 mg/mL ( Crapo , 2000 ) ; No significant change regular asthma medication acute asthma exacerbation require oral corticosteroid double ICS dosage , hospitalization , emergency room visit , unscheduled health care provider visit asthma least 6 week prior screen time study drug administration ; No history intubation admission intensive care unit asthma ; Sexually active woman , unless surgically sterile least 1 year postmenopausal , must use effective method avoid pregnancy ( include oral implanted contraceptive , intrauterine device , female condom , diaphragm spermicide , cervical cap , abstinence , use condom sexual partner sterile sexual partner ) 21 day prior study drug administration Study Day 0 , must agree continue use precaution Study Day 126 . Cessation birth control point discuss responsible physician . Sexually active men , unless surgically sterile , must likewise use effective method birth control ( condom ) must agree continue use precaution Study Day 126 ; Able follow study procedure include ability provide spirometry reading meet American Thoracic Society ( ATS ) /European Respiratory Society ( ERS ) standard ( Miller , 2005 ) ; Ability complete study period , include followup period , 126 day ; Willing forego form experimental treatment study procedure study . Receipt MEDI528 previous clinical study ; History allergy reaction component study drug formulation medication , topical lidocaine , administer bronchoscopy ; Lung disease allergic asthma ( eg , chronic bronchitis ) ; FEV1 &lt; 70 % predicted value ; Use systemic immunosuppressive drug include systemic corticosteroid ( topical corticosteroid permit ) , ICS dose &gt; 800 μg/day budesonide equivalent , longacting β2 agonist ( eg , salmeterol ) , leukotriene antagonist , cromolyn sodium , nedocromil sodium , theophylline , omalizumab , medication asthma except shortacting β2 agonist ( need ) within 4 week prior screen administration study drug ; Current use βadrenergic antagonist ( eg , propranolol ) ; Any disease illness , asthma , may require use systemic corticosteroid study period ; Upper low respiratory tract infection within 8 week screen ; Acute illnesses evidence clinically significant active infection , fever ≥ 38.0°C ( 100.5°F ) screening time study drug administration Study Day 0 ; Current allergy vaccination therapy ( desensitization immunotherapy ) less 3 month stable maintenance dos prior baseline segmental allergen challenge . The allergy vaccination must include desensitization allergen use segmental allergen challenge ; Receipt investigational drug therapy within 30 day biologic ( ) within 5 halflives agent prior study drug administration Study Day 126 ; Receipt therapy leukocytedepleting agent ( eg , rituximab , alemtuzumab ) unless recovery white cell count document screening ; Pregnancy ( sexually active female must negative serum urine pregnancy test screen negative urine pregnancy test prior study drug administration Study Day 0 ) ; Is nurse mother time screening ; Evidence infection hepatitis B C virus , HIV1 HIV2 , active infection hepatitis A ; History significant systemic disease ( eg , cancer , infection , hematological , renal , hepatic , coronary artery disease cardiovascular disease , endocrinologic , neurologic , rheumatologic , gastrointestinal disease ) ; History cancer basal cell carcinoma cervical carcinomainsitu treat apparently successful curative therapy ( remission ≥ 1 year prior screen ) ; History primary immunodeficiency ; History pancreatitis currently active gastroduodenal ulcer ; History coagulation disorder abnormal PT PTT test result screen ; History lifelong urinary retention ; History use tobacco product one cigarette per month equivalent within 1 year prior screen history smoking ≥ 10 packyears ; History anaphylaxis ; Elective surgery plan time screen Study Day 126 ; Clinically significant abnormality ( asthma ) upon physical examination prior study drug administration Study Day 0 ; Clinically significant abnormality , determine investigator , 12lead ECG chest radiograph time screening ; At time screen , follow : hemoglobin , total white blood cell count ( WBC ) , platelet count , sodium ( Na ) , potassium ( K ) , chloride ( Cl ) , carbon dioxide ( CO2 ) normal range ; aspartate transaminase ( AST ) , alanine transaminase ( ALT ) , blood urea nitrogen ( BUN ) , amylase , lipase , serum creatinine upper limit normal ( ULN ) ; abnormal laboratory value screen panel judge principal investigator clinically significant ; No detectable level IL9 Baseline Visit 2 ' BAL sample , find upon physical examination history disease , opinion principal investigator medical monitor , may compromise safety patient study confound analysis study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>